

Protein Drugs-Europe Market Status and Trend Report 2013-2023

<https://marketpublishers.com/r/PCAB75AAFC8EN.html>

Date: December 2017

Pages: 144

Price: US\$ 3,480.00 (Single User License)

ID: PCAB75AAFC8EN

Abstracts

Report Summary

Protein Drugs-Europe Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Protein Drugs industry, standing on the readers' perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:

Whole Europe and Regional Market Size of Protein Drugs 2013-2017, and development forecast 2018-2023

Main market players of Protein Drugs in Europe, with company and product introduction, position in the Protein Drugs market

Market status and development trend of Protein Drugs by types and applications

Cost and profit status of Protein Drugs, and marketing status

Market growth drivers and challenges

The report segments the Europe Protein Drugs market as:

Europe Protein Drugs Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):

Germany

United Kingdom

France

Italy

Spain

Benelux

Russia

Europe Protein Drugs Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):

Antibody Drugs

Peptide Hormones

Blood Products

Enzymes

Europe Protein Drugs Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)

AIDS

Cancer

Hepatitis

Diabetes

Others

Europe Protein Drugs Market: Players Segment Analysis (Company and Product introduction, Protein Drugs Sales Volume, Revenue, Price and Gross Margin):

Eli Lilly

Abbott Laboratories

UCB Group

Schering-Plough Corporation

Genentech

Johnson?Johnson

Bristol-Myers Squibb

Novo Nordisk

Biogen Idec

Dendreon Corporation

Amgen

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.

Contents

CHAPTER 1 OVERVIEW OF PROTEIN DRUGS

- 1.1 Definition of Protein Drugs in This Report
- 1.2 Commercial Types of Protein Drugs
 - 1.2.1 Antibody Drugs
 - 1.2.2 Peptide Hormones
 - 1.2.3 Blood Products
 - 1.2.4 Enzymes
- 1.3 Downstream Application of Protein Drugs
 - 1.3.1 AIDS
 - 1.3.2 Cancer
 - 1.3.3 Hepatitis
 - 1.3.4 Diabetes
 - 1.3.5 Others
- 1.4 Development History of Protein Drugs
- 1.5 Market Status and Trend of Protein Drugs 2013-2023
 - 1.5.1 Europe Protein Drugs Market Status and Trend 2013-2023
 - 1.5.2 Regional Protein Drugs Market Status and Trend 2013-2023

CHAPTER 2 EUROPE MARKET STATUS AND FORECAST BY REGIONS

- 2.1 Market Status of Protein Drugs in Europe 2013-2017
- 2.2 Consumption Market of Protein Drugs in Europe by Regions
 - 2.2.1 Consumption Volume of Protein Drugs in Europe by Regions
 - 2.2.2 Revenue of Protein Drugs in Europe by Regions
- 2.3 Market Analysis of Protein Drugs in Europe by Regions
 - 2.3.1 Market Analysis of Protein Drugs in Germany 2013-2017
 - 2.3.2 Market Analysis of Protein Drugs in United Kingdom 2013-2017
 - 2.3.3 Market Analysis of Protein Drugs in France 2013-2017
 - 2.3.4 Market Analysis of Protein Drugs in Italy 2013-2017
 - 2.3.5 Market Analysis of Protein Drugs in Spain 2013-2017
 - 2.3.6 Market Analysis of Protein Drugs in Benelux 2013-2017
 - 2.3.7 Market Analysis of Protein Drugs in Russia 2013-2017
- 2.4 Market Development Forecast of Protein Drugs in Europe 2018-2023
 - 2.4.1 Market Development Forecast of Protein Drugs in Europe 2018-2023
 - 2.4.2 Market Development Forecast of Protein Drugs by Regions 2018-2023

CHAPTER 3 EUROPE MARKET STATUS AND FORECAST BY TYPES

- 3.1 Whole Europe Market Status by Types
 - 3.1.1 Consumption Volume of Protein Drugs in Europe by Types
 - 3.1.2 Revenue of Protein Drugs in Europe by Types
- 3.2 Europe Market Status by Types in Major Countries
 - 3.2.1 Market Status by Types in Germany
 - 3.2.2 Market Status by Types in United Kingdom
 - 3.2.3 Market Status by Types in France
 - 3.2.4 Market Status by Types in Italy
 - 3.2.5 Market Status by Types in Spain
 - 3.2.6 Market Status by Types in Benelux
 - 3.2.7 Market Status by Types in Russia
- 3.3 Market Forecast of Protein Drugs in Europe by Types

CHAPTER 4 EUROPE MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY

- 4.1 Demand Volume of Protein Drugs in Europe by Downstream Industry
- 4.2 Demand Volume of Protein Drugs by Downstream Industry in Major Countries
 - 4.2.1 Demand Volume of Protein Drugs by Downstream Industry in Germany
 - 4.2.2 Demand Volume of Protein Drugs by Downstream Industry in United Kingdom
 - 4.2.3 Demand Volume of Protein Drugs by Downstream Industry in France
 - 4.2.4 Demand Volume of Protein Drugs by Downstream Industry in Italy
 - 4.2.5 Demand Volume of Protein Drugs by Downstream Industry in Spain
 - 4.2.6 Demand Volume of Protein Drugs by Downstream Industry in Benelux
 - 4.2.7 Demand Volume of Protein Drugs by Downstream Industry in Russia
- 4.3 Market Forecast of Protein Drugs in Europe by Downstream Industry

CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF PROTEIN DRUGS

- 5.1 Europe Economy Situation and Trend Overview
- 5.2 Protein Drugs Downstream Industry Situation and Trend Overview

CHAPTER 6 PROTEIN DRUGS MARKET COMPETITION STATUS BY MAJOR PLAYERS IN EUROPE

- 6.1 Sales Volume of Protein Drugs in Europe by Major Players
- 6.2 Revenue of Protein Drugs in Europe by Major Players

- 6.3 Basic Information of Protein Drugs by Major Players
 - 6.3.1 Headquarters Location and Established Time of Protein Drugs Major Players
 - 6.3.2 Employees and Revenue Level of Protein Drugs Major Players
- 6.4 Market Competition News and Trend
 - 6.4.1 Merger, Consolidation or Acquisition News
 - 6.4.2 Investment or Disinvestment News
 - 6.4.3 New Product Development and Launch

CHAPTER 7 PROTEIN DRUGS MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA

- 7.1 Eli Lilly
 - 7.1.1 Company profile
 - 7.1.2 Representative Protein Drugs Product
 - 7.1.3 Protein Drugs Sales, Revenue, Price and Gross Margin of Eli Lilly
- 7.2 Abbott Laboratories
 - 7.2.1 Company profile
 - 7.2.2 Representative Protein Drugs Product
 - 7.2.3 Protein Drugs Sales, Revenue, Price and Gross Margin of Abbott Laboratories
- 7.3 UCB Group
 - 7.3.1 Company profile
 - 7.3.2 Representative Protein Drugs Product
 - 7.3.3 Protein Drugs Sales, Revenue, Price and Gross Margin of UCB Group
- 7.4 Schering-Plough Corporation
 - 7.4.1 Company profile
 - 7.4.2 Representative Protein Drugs Product
 - 7.4.3 Protein Drugs Sales, Revenue, Price and Gross Margin of Schering-Plough Corporation
- 7.5 Genentech
 - 7.5.1 Company profile
 - 7.5.2 Representative Protein Drugs Product
 - 7.5.3 Protein Drugs Sales, Revenue, Price and Gross Margin of Genentech
- 7.6 Johnson?Johnson
 - 7.6.1 Company profile
 - 7.6.2 Representative Protein Drugs Product
 - 7.6.3 Protein Drugs Sales, Revenue, Price and Gross Margin of Johnson?Johnson
- 7.7 Bristol-Myers Squibb
 - 7.7.1 Company profile
 - 7.7.2 Representative Protein Drugs Product

- 7.7.3 Protein Drugs Sales, Revenue, Price and Gross Margin of Bristol-Myers Squibb
- 7.8 Novo Nordisk
 - 7.8.1 Company profile
 - 7.8.2 Representative Protein Drugs Product
 - 7.8.3 Protein Drugs Sales, Revenue, Price and Gross Margin of Novo Nordisk
- 7.9 Biogen Idec
 - 7.9.1 Company profile
 - 7.9.2 Representative Protein Drugs Product
 - 7.9.3 Protein Drugs Sales, Revenue, Price and Gross Margin of Biogen Idec
- 7.10 Dendreon Corporation
 - 7.10.1 Company profile
 - 7.10.2 Representative Protein Drugs Product
 - 7.10.3 Protein Drugs Sales, Revenue, Price and Gross Margin of Dendreon Corporation
- 7.11 Amgen
 - 7.11.1 Company profile
 - 7.11.2 Representative Protein Drugs Product
 - 7.11.3 Protein Drugs Sales, Revenue, Price and Gross Margin of Amgen

CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF PROTEIN DRUGS

- 8.1 Industry Chain of Protein Drugs
- 8.2 Upstream Market and Representative Companies Analysis
- 8.3 Downstream Market and Representative Companies Analysis

CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF PROTEIN DRUGS

- 9.1 Cost Structure Analysis of Protein Drugs
- 9.2 Raw Materials Cost Analysis of Protein Drugs
- 9.3 Labor Cost Analysis of Protein Drugs
- 9.4 Manufacturing Expenses Analysis of Protein Drugs

CHAPTER 10 MARKETING STATUS ANALYSIS OF PROTEIN DRUGS

- 10.1 Marketing Channel
 - 10.1.1 Direct Marketing
 - 10.1.2 Indirect Marketing
 - 10.1.3 Marketing Channel Development Trend

10.2 Market Positioning

10.2.1 Pricing Strategy

10.2.2 Brand Strategy

10.2.3 Target Client

10.3 Distributors/Traders List

CHAPTER 11 REPORT CONCLUSION

CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE

12.1 Methodology/Research Approach

12.1.1 Research Programs/Design

12.1.2 Market Size Estimation

12.1.3 Market Breakdown and Data Triangulation

12.2 Data Source

12.2.1 Secondary Sources

12.2.2 Primary Sources

12.3 Reference

I would like to order

Product name: Protein Drugs-Europe Market Status and Trend Report 2013-2023

Product link: <https://marketpublishers.com/r/PCAB75AAFC8EN.html>

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/PCAB75AAFC8EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970